PET/CT assessment of neuroendocrine tumors of the lung with special emphasis on bronchial carcinoids

Tumor Biology

Volumn 35, Issue 9, 2014, Pages 8369-8377

  Lococo, Filippo ^a   Cesario, Alfredo ^b   Paci, Massimiliano ^a   Filice, Angelina ^c   Versari, Annibale ^c   Rapicetta, Cristian ^a   Ricchetti, Tommaso ^a   Sgarbi, Giorgio ^a   Alifano, Marco ^d   Cavazza, Alberto ^a   Treglia, Giorgio ^e  

^a S MARIA NUOVA HOSPITAL   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c Department of Nuclear Medicine ^*  (Italy)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

Author keywords

Functional imaging; Neuroendocrine tumors; PET CT; Pulmonary tumors

Indexed keywords

DOTANOC GALLIUM GA 68; DOTATATE GALLIUM GA 68; DOTATOC GALLIUM GA 68; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; TETRAXETAN; UNCLASSIFIED DRUG; GA(III)-DOTATOC; OCTREOTIDE; ORGANOMETALLIC COMPOUND;

BRONCHUS CARCINOID; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CLINICAL ASSESSMENT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG UPTAKE; HISTOPATHOLOGY; HUMAN; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG TUMOR; NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; PULMONARY NEUROENDOCRINE TUMOR; RECEPTOR BINDING; REVIEW; SMALL CELL LUNG CANCER; TUMOR DIFFERENTIATION; ANALOGS AND DERIVATIVES; BRONCHIAL NEOPLASMS; CARCINOID TUMOR; DIAGNOSTIC USE; LUNG NEOPLASMS; MORTALITY; NEUROENDOCRINE TUMORS; PROCEDURES; RADIOGRAPHY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

BRONCHIAL NEOPLASMS; CARCINOID TUMOR; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84919843331     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2102-y     Document Type: Review

References (50)

1. Benson RE, Rosado-de-Christenson ML, Martínez-Jiménez S, Kunin JR, Pettavel PP. Spectrum of pulmonary neuroendocrine proliferations and neoplasms. Radiographics. 2013;33:1631–49.
2. Okoye CC, Jablons DM, Jahan TM, Kukreja J, Cardozo S, Yom SS. Divergent management strategies for typical versus atypical carcinoid tumors of the thoracic cavity. Am J Clin Oncol. 2013. doi:10.1097/COC.0b013e31827a7f6d.
3. Johnson R, Trocha S, McLawhorn M, Worley M, Wheeler G, Thompson L, et al. Histology, not lymph node involvement, predicts long-term survival in bronchopulmonary carcinoids. Am Surg. 2011;77:1669–74.
4. Cueto A, Burigana F, Nicolini A, Lugnani F. Neuroendocrine tumors of the lung: hystological classification, diagnosis, traditional and new therapeutic approaches. Curr Med Chem. 2014;21:1107–16.
5. Rindi G, Klersy C, Inzani F, Fellegara G, Ampollini L, Ardizzoni A, et al. Grading the neuroendocrine tumors of the lung: an evidence-based proposal. Endocr Relat Cancer. 2013;21:1–16.
6. Ambrosini V, Nicolini S, Caroli P, Nanni C, Massaro A, Marzola MC, et al. PET/CT imaging in different types of lung cancer: an overview. Eur J Radiol. 2012;81:988–1001.
7. Treglia G, Cason E, Fagioli G. Recent applications of nuclear medicine in diagnostics (first part). Ital J Med. 2010;4:84–91.
8. Travis WD, Linnoila RI, Tsokos MG, Hitchcock CL, Cutler Jr GB, Nieman L, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol. 1991;15:529–53.
9. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press; 2004. World Health Organization Classification of Tumours; vol 10.
10. Nassar AA, Jaroszewski DE, Helmers RA, Colby TV, Patel BM, Mookadam F. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: a systematic overview. Am J Respir Crit Care Med. 2011;184:8–16.
11. Vansteenkiste J, Fischer BM, Dooms C, Mortensen J. Positron emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol. 2004;5:531–40.
12. Higashi K, Ueda Y, Ayabe K, Sakurai A, Seki H, Nambu Y, et al. FDG PET in the evaluation of the aggressiveness of pulmonary adenocarcinoma: correlation with histopathological features. Nucl Med Commun. 2000;21:707–14.
13. 18F-FDG uptake on PET in pulmonary neuroendocrine tumors. Anticancer Res. 2013;33:4219–28.
14. Song YS, Lee WW, Chung JH, Park SY, Kim YK, Kim SE. Correlation between FDG uptake and glucose transporter type 1 expression in neuroendocrine tumors of the lung. Lung Cancer. 2008;61(1):54–60.
15. Erasmus JJ, McAdams HP, Patz EF, Coleman RE, Ahuja V, Goodman PC. Evaluation of primary pulmonary carcinoid tumors using FDG PET. AJR Am J Roentgenol. 1998;170:1369–73.
16. Kruger K, Buck AK, Blumstein NM, Pauls S, Schelzig H, Kropf C, et al. Use of integrated FDG-PET/CT imaging in pulmonary carcinoid tumors. J Int Med. 2006;260:545–50.
17. Chong S, Lee KS, Kim BT, Choi JY, Yi CA, Chung MJ, et al. Integrated PET/CT of pulmonary neuroendocrine tumors: diagnostic and prognostic implications. AJR Am J Roentgenol. 2007;188:1223–31.
18. Daniels CE, Lowe VJ, Aubry MC, Allen MS, Jett JR. The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules. Chest. 2007;131:255–60.
19. Kayani I, Conry BG, Groves AM, Win T, Dickson J, Caplin M, et al. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors. J Nucl Med. 2009;50:1927–32.
20. Jindal T, Kumar A, Venkitaraman B, Meena M, Kumar R, Malhotra A, et al. Evaluation of the role of [18F]FDG-PET/CT and [68Ga]DOTATOC-PET/CT in differentiating typical and atypical pulmonary carcinoids. Cancer Imaging. 2011;11:70–5.
21. Kuyumcu S, Adalet I, Sanli Y, Turkmen C, Ozkan ZG, Yilmazbayhan D. Somatostatin receptor scintigraphy with 111In-octreotide in pulmonary carcinoid tumours correlated with pathological and 18FDG PET/CT findings. Ann Nucl Med. 2012;26:689–97.
22. Venkitaraman B, Karunanithi S, Kumar A, Khilnani GC, Kumar R. Role of 68Ga-DOTATOC PET/CT in initial evaluation of patients with suspected bronchopulmonary carcinoid. Eur J Nucl Med Mol Imaging. 2014;41:856–64.
23. Stefani A, Franceschetto A, Nesci J, Aramini B, Proli C, Kaleci S, et al. Integrated FDG-PET/CT imaging is useful in the approach to carcinoid tumors of the lung. J Cardiothorac Surg. 2013;8:223.
24. Moore W, Freiberg E, Bishawi M, Halbreiner MS, Matthews R, Baram D, et al. FDG-PET imaging in patients with pulmonary carcinoid tumor. Clin Nucl Med. 2013;38:501–5.
25. Alpay L, Lacin T, Kanbur S, Kiral H, Ersoz E, Bayram S, et al. Are the 18F-FDG positron emission tomography/computed tomography findings in bronchopulmonary carcinoid tumors different than expected? Hell J Nucl Med. 2013;16:213–7.
26. Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence and survival. J Thorac Cardiovasc Surg. 2005;130:151–9.
27. Blum R, MacManus MP, Rischin D, Michael M, Ball D, Hicks RJ. Impact of positron emission tomography on the management of patients with small-cell lung cancer: preliminary experience. Am J Clin Oncol. 2004;27:164–71.
28. Pandit N, Gonen M, Krug L, Larson SM. Prognostic value of [18F]FDG-PET imaging in small cell lung cancer. Eur J Nucl Med Mol Imaging. 2003;30:78–84.
29. Tsuta K, Wistuba II, Moran CA. Differential expression of somatostatin receptors 1–5 in neuroendocrine carcinoma of the lung. Pathol Res Pract. 2012;208:470–4.
30. Cascini GL, Cuccurullo V, Tamburrini O, Rotondo A, Mansi L. Peptide imaging with somatostatin analogues: more than cancer probes. Curr Radiopharm. 2013;6:36–40.
31. Zhernosekov KP, Filosofov DV, Baum RP, Aschoff P, Bihl H, Razbash AA, et al. Processing of generator-produced 68Ga for medical application. J Nucl Med. 2007;48:1741–8.
32. Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging. 2007;34:982–93.
33. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508–18.
34. Treglia G, Castaldi P, Rindi G, Giordano A, Rufini V. Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine. 2012;42:80–7.
35. Sollini M, Erba PA, Fraternali A, Casali M, Di Paolo ML, Froio A, et al. PET and PET/CT with 68 gallium-labeled somatostatin analogues in non GEP-NETs tumors. Sci World J. 2014;2014:194123.
36. Ambrosini V, Castellucci P, Rubello D, Nanni C, Musto A, Allegri V, et al. 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Nucl Med Commun. 2009;30:281–6.
37. Jindal T, Kumar A, Venkitaraman B, Dutta R, Kumar R. Role of (68)Ga-DOTATOC PET/CT in the evaluation of primary pulmonary carcinoids. Korean J Intern Med. 2010;25:386–91.
38. Sollini M, Farioli D, Froio A, Chella A, Asti M, Boni R, et al. Brief report on the use of radiolabeled somatostatin analogs for the diagnosis and treatment of metastatic small-cell lung cancer patients. J Thorac Oncol. 2013;8:1095–101.
39. Vanhagen PM, Krenning EP, Reubi JC, Kwekkeboom DJ, Bakker WH, Mulder AH, et al. Somatostatin analogue scintigraphy in granulomatous diseases. Eur J Nucl Med. 1994;21:497–502.
40. Treglia G, Farchione A, Stefanelli A, Brizi MG, Larghi A, Inzani F, et al. Masking effect of chronic pancreatitis in the interpretation of somatostatin receptor positron emission tomography in pancreatic neuroendocrine tumors. Pancreas. 2013;42:726–8.
41. Treglia G, Ceriani L, Ruberto T, Paone G, Bertagna F, Giovanella L. A case of optic neuritis incidentally detected by somatostatin receptor scintigraphy. Rev Esp Med Nucl Image Mol. 2014;33:189–90.
42. Lococo F, Cafarotti S, Filice A, Bertagna F, Treglia G. A false positive finding on the PET of somatostatin receptor due to a chondromyxoid fibroma. Rev Esp Med Nucl Image Mol. 2013. doi:10.1016/j.remn.2013.09.003.
43. Treglia G, Giovanella L, Lococo F. Evolving role of PET/CT with different tracers in the evaluation of pulmonary neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014;41:853–5.
44. Lococo F, Treglia G. Which is the best strategy for diagnosing bronchial carcinoid tumours? The role of dual tracer PET/CT scan. Hell J Nucl Med. 2014;17:7–9.
45. Paci M, Lococo F, Rapicetta C, Roncali M, Cavazza A, Treglia G, et al. Synchronous bilateral bronchial carcinoid diagnosed with combined dual tracer ((18)F-FDG and (68)Ga-DOTATOC) PET/CT scans. Rev Esp Med Nucl Image Mol. 2013. doi:10.1016/j.remn.2013.08.007.
46. Kumar A, Jindal T, Dutta R, Kumar R. Functional imaging in differentiating bronchial masses: an initial experience with a combination of (18)F-FDG PET-CT scan and (68)Ga DOTA-TOC PET-CT scan. Ann Nucl Med. 2009;23:745–51.
47. Taralli S, Treglia G, Perotti G, Graziano P, Cardillo G, Castaldi P, et al. A rare case of synchronous bilateral pulmonary neuroendocrine tumor detected by 68Ga-DOTANOC PET/CT. Clin Nucl Med. 2012;37:e91–4.
48. Treglia G, Lococo F, Petrone G, Inzani F, Perotti G, Porziella V, et al. Pulmonary neuroendocrine tumor incidentally detected by 18F-CH PET/CT. Clin Nucl Med. 2013;38:e196–9.
49. Wahlberg J, Ekman B. Atypical or typical adrenocorticotropic hormone-producing pulmonary carcinoids and the usefulness of 11C-5-hydroxytryptophan positron emission tomography: two case reports. J Med Case Rep. 2013;7:80.
50. Rufini V, Treglia G, Montravers F, Giordano A. Diagnostic accuracy of [18F]DOPA PET and PET/CT in patients with neuroendocrine tumors: a meta-analysis. Clin Transl Imaging. 2013;1:111–22.